catalyst calendar
← Catalyst calendar

CGEM biotech catalysts & pipeline

CULLINAN THERAPEUTICS INC · Data as of 2026-11-15

Upcoming catalysts

zipalertinib — Topline data

Late 2026

Taiho expects to obtain top-line results by the end of 2026.
Source filing

zipalertinib — NDA/BLA submission

Late 2026

After agreement with the U.S. FDA, Real-Time Oncology Review program submission process initiated; completion of NDA submission expected by year-end 2026
Source filing

CLN-978 — Initial data

Q4 2026

In Q4 2026, the Company plans to share initial data from Part A (single target dose escalation) with a focus on safety and B cell depletion in peripheral blood and tissue, as well as other biomarker data and preliminary clinical activity data.
Source filing

velinotamig (CLN-803) — Interim data

Q4 2026

Additional multi-dose regimen data in patients with SLE from the Genrix Bio clinical trial in China expected to be shared in Q4 2026
Source filing

CLN-978 — Clinical data readout

December

CLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA and Sjögren's disease in December
Source filing

zipalertinib — PDUFA

Feb 27

An NDA seeking accelerated approval for zipalertinib monotherapy in this indication remains under FDA review, with a Prescription Drug User Fee Act (PDUFA) target action date of February 27, 2027.
Source filing

CLN-049 — Conference presentation

Dec 12

Session Date: December 12, 2026
Source filing

velinotamig (CLN-803) — Conference presentation

Dec 12

Session Date: December 12, 2026
Source filing

velinotamig (CLN-803) — Conference presentation

Dec 13

Session Date: December 13, 2026
Source filing

Explore the free biotech catalyst calendar